Hepatitis C (HCV)-related liver disease has become one of the leading causes of death in HIV patients. With the development of new direct-acting antivirals for HCV, treatment regimens have become shorter, more effective, and easier to tolerate without interferon. However, cost may be a significant impediment to the widespread use of these newer agents in both resource-rich and resource-poor settings. In HIV patients, treatment for HCV is not always as straightforward compared with HCV monoinfected patients due to potential drug-drug interactions. In this article, we will examine by genotypes the FDA approved direct-acting antivirals, as well as those in clinical trials that will soon be FDA-approved focusing on data in HCV/HIV co-infection. Preferred agents for HCV treatment and potential drug-drug interactions with antiretroviral therapy (ART) will be highlighted.
Introduction
A n estimated one-third of patients infected with HIV are co-infected with hepatitis C (HCV). Since 2007, the rate of death resulting from HCV has exceeded the rate of death due to HIV. 1 In HIV-infected patients, life expectancy in those with HIV alone is approaching that of the general population, but not among those with HIV and HCV co-infection. In one study, the projected life expectancy in co-infected patients was approximately 20 years shorter than those with HIV alone, 2 due in part to increasing rates of hepatocellular carcinoma (HCC). 3 Historical rates of sustained viral response (SVR) with pegylated interferon (PegIFN) and ribavirin (RBV) therapy in genotype 1 were 29%. 4 In addition, PegIFN had many side effects, and many patients with severe mental illness were excluded. RBV interacts with specific nucleoside reverse transcriptase inhibitors (NRTI) such as didanosine and stavudine, leading to a higher risk of lactic acidosis, and RBV-induced anemia can be exacerbated by zidovudine. 5, 6 Furthermore, the combination of PegIFN and RBV had to be administered for 48 weeks in genotype 1 patients.
The need for new therapies was clear. Over the last decade, significant advancement in our understanding of the HCV life cycle has led to the development of directly acting antivirals (DAAs), which are focused on three drug-targets that halt the replication of HCV. They are protease inhibitors (PIs) targeting the NS3A/4A protein, which have names ending in ''-evir''; polymerase inhibitors targeting the NS5B polymerase and are named with ''-buvir''; and inhibitors of the NS5A polymerase, which are named with ''-asvir''.
In May 2011, the FDA approved the first-in-class NS3/4A serine PIs boceprevir and telaprevir. Both drugs significantly increased SVR rates in HCV mono-and HIV co-infected patients. However, both PIs only had activity for genotype 1 and required administration with PegIFN/RBV. Response guided therapy (RGT) did allow some patients to shorten therapy to 24 weeks instead of 48 weeks. Nevertheless, high pill burden, and side effects of the PI, PegIFN, and RBV remain as treatment barriers.
In December 2013, the FDA approved the first-in-class NS5B polymerase inhibitor sofosbuvir and second generation NS3/4A PI, simeprevir. The approval of these two DAAs opened another era of HCV treatment. Sofosbuvir therapy is not limited to genotype 1 and IFN-free regimens were first approved for HCV genotypes 2 and 3. In response to new treatment options, the American Association for the Study of Liver Disease (AASLD) and Infectious Disease Society of America (IDSA) collaboratively published recommendations for testing, managing, and treating HCV in January 2014, with revisions in December 2014. 7 Major side effects of PegIFN include flu-like symptoms, fatigue, depression, cytopenia, and rash. RBV-related toxicities include anemia, fatigue, irritability, and insomnia. Because of these toxicities, PegIFN is no longer recommended in any treatment regimen for genotype 1 patients. The goal of therapy is to use an alloral regimen when possible and shorter therapy when available (Table 1) . A HCV RNA can be obtained at 4 weeks to measure compliance but no stopping rules apply in current recommended regimens. A complete blood count should be taken at weeks 2 and 4, and then monthly to evaluate for anemia if using a regimen containing RBV. As most relapses occur within the first 4 weeks post-treatment, a 4-week posttreatment HCV RNA can be obtained. However, SVR is measured at 12 weeks post-treatment. No detectable virus 12 weeks after completing a course of treatment is equivalent to a cure.
Genotype 1

Sofosbuvir/ledipasvir
The fixed dose combination of sofosbuvir/ledipasvir, a combination of an NS5B with an NS5A polymerase inhibitor, was FDA approved in October 2014. The phase 3 ION studies of this fixed-dose combination demonstrate SVR of 94% for 8 weeks of sofosbuvir/ledipasvir, 93% for sofosbuvir/ ledipasvir plus RBV for 8 weeks, and 95% with sofosbuvir/ ledipasvir for 12 weeks in treatment-naïve, non-cirrhotic patients. 8 In treatment-experienced patients, the SVR was 94% with 12 weeks of sofosbuvir/ledipasvir, 96% in those who received sofosbuvir/ledipasvir plus RBV for 12 weeks, and 99% in those receiving the fixed dose combination with or without RBV for 24 weeks. 9 Sofosbuvir/ledipasvir has been approved for 8 weeks in treatment-naïve, non-cirrhotic patients, with HCV RNA < 6 million copies/ml or 12 weeks in treatment-naïve cirrhotic patients or those with HCV RNA > 6 million copies/mL. For treatment-experienced cirrhotic patients, the regimen should be extended to 24 weeks. This is the first FDA-approved regimen for HCV genotype 1 that does not require PegIFN/RBV. Ledipasvir solubility decreases as pH increases, increased gastric pH is expected to decrease ledipasvir concentration. H2 blockers should be taken 12 h apart and proton-pump inhibitors should be avoided. 10 For HCV/HIV co-infected patients, a study conducted by NIAID/CC Hepatitis C ERADICATE team in this population reports findings of 97-100% SVR in both ART treated and untreated patients. 11 PK data of sofosbuvir/ledipasvir from ION-4 study shows ledipasvir can be co-administered with raltegravir, tenofovir/emtricitabine/efavirenz, or rilpivirine without dose adjustment, but patients taking tenofovir/ emtricitabine/efavirenz should be monitored for tenofovir toxicity. 12 Based on the package insert, a HIV boosted PI or cobicistat-containing regimen used with tenofovir is not recommended due to lack of safety data on increased tenofovir concentration (see Table 2 for drug-drug interactions). 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Further PK data of sofosbuvir/ledipasvir with boosted PIs and cobicistat/elvitegravir are pending. Ledipasvir is minimally metabolized and primarily eliminated through the gut. 23 Thus, sofosbuvir/ledipasvir could also be used in patients with mild to moderate renal dysfunction (GFR > 30 mL/min).
Sofosbuvir plus simeprevir
In November 2014, simeprevir was approved by FDA to be used in combination with sofosbuvir. Simeprevir and sofosbuvir should be used for 12 weeks for non-cirrhotic patients and 24 weeks in cirrhotic patients, regardless of previous treatment experiences. In the COSMOS study, sofosbuvir plus simeprevir with or without RBV for 12 weeks yielded SVR12 of 96% in patients with mild fibrosis (Metavir F0-2) and 86% in patients with advanced fibrosis (Metavir F3-4). The SVR was 100% with the same regimen for 24 weeks in patients with cirrhosis; however, only 10 patients were enrolled. 24 No data from clinical trials exist about the combination of sofosbuvir and simeprevir in HIV-infected patients. Although it would be expected to yield results similar to those seen in mono-infected patients, the drug-drug interactions between simeprevir and many ART regimens would affect administration in co-infected patients. Simeprevir is metabolized through CYP3A and its concomitant use with boosted HIV PIs, efavirenz, etravirine, and tenofovir/emtricitabine/cobicistat/ elvitegravir is not recommended; it may be administered with raltegravir, rilpivirine, maraviroc, and tenofovir. 21, 22 Sofosbuvir is a substrate of drug transporters P-gp, so drugs that are potent P-gp inducers such as rifampin and St. John's Wort are contraindicated. Sofosbuvir has no significant interaction with most ART including tenofovir, emtricitabine, efavirenz, rilpivirine, and darunavir. 25 Boosted tipranavir, which decreases the concentration of sofosbuvir, is contraindicated. 13 Caution should be used when administering simeprevir and sofosbuvir in patients with Child Pugh class B and C cirrhosis, as there are no data on drug levels in this population.
Paritaprevir/r-ombitasvir and dasabuvir (3D)
Another IFN-free all-oral therapy, which obtained FDA approval in December 2014, is a combination of fixed-dose ombitasvir (NS5A inhibitor)/paritaprevir (NS3/4A PI) boosted with ritonavir daily and dasabuvir (NS5B inhibitor) twice daily, also known as 3D, given for 12-24 weeks. It is recommended to treat genotype 1a without cirrhosis with the 3D regimen and RBV for 12 weeks, but extend for 24 weeks in those with cirrhosis. Genotype 1b patients without cirrhosis can be treated with the 3D regimen alone for 12 weeks and those with cirrhosis can be treated with 3D regimen and RBV for 12 weeks. 7 In clinical trials when combined with RBV, this regimen produced ‡ 96% SVR in treatment-naïve and -experienced patients. 26, 27 The most common adverse events were headache, fatigue, and pruritus. Limited PK data show no drug interactions with tenofovir, emtricitabine, atazanavir, or raltegravir. The 3D regimen is not recommended with efavirenz, lopinavir/ ritonavir, or rilpivirine. Additional studies are being conducted with darunavir. The TURQUOISE-1 trial which enrolled HCV/HIV co-infected patients on either atazanavir or raltegravir regimen treated with 3D + RBV for 12 or 24 weeks has SVR12 of 94%. 28 Dolutegravir is not expected to have drug interactions.
FDA approved but no longer recommended
Simeprevir. Simeprevir is a second-generation PI administered once daily at a dose of 150 mg. The data indicate that, in patients who did not meet RGT criteria, extension of treatment to 48 weeks did not significantly improve SVR. 29, 30 Thus, the drug is administered with PegIFN/RBV for 12 weeks, followed by PegIFN/RBV alone to complete 24 weeks of treatment in genotype 1b or genotype 1a without Q80K polymorphism.
14 Pooled overall response rates from QUEST 1 and QUEST 2 showed an 80% SVR compared with 50% in the placebo group. 31 In HIV-infected patients, Study C212 enrolled treatmentnaïve and -experienced patients and achieved overall SVR of 74-79% in treatment-naïve, 87% in prior relapsers, 70% in partial responders, and 57% in null responders. Overall SVR rates were 80% for patients with mild fibrosis and 64% for those with advanced fibrosis. 32 Approximately 28% of patients had the Q80K polymorphism that has been shown to reduce SVR in HCV mono-infected patients treated with simeprevir, 14 but this was not found in co-infected patients.
Sofosbuvir. Sofosbuvir is a NS5B polymerase inhibitor formulated as a 400 mg tablet taken once daily. In treatmentnaïve patients, sofosbuvir combined with PegIFN and RBV is given for 12 weeks. Sofosbuvir has been studied mostly in treatment-naïve patients with genotype 1. In the phase 3 NEUTRINO trial, 90% SVR was achieved in treatment-naïve patients with sofosbuvir plus PegIFN/RBV for 12 weeks; but less than 20% of the patients had cirrhosis. 33 Unlike PegIFN/ RBV, in which cirrhotic patients had significantly lower SVR, cirrhotic patients in the NEUTRINO study had an 80% SVR compared with a 92% SVR in non-cirrhotic patients treated with sofosbuvir, PegIFN/RBV for genotype 1 and 4. 33 The phase 2 ELECTRON trial was the only study to examine an IFN-free regimen of sofosbuvir and RBV for 12 weeks in treatment-experienced patients (prior nonresponders). SVR in this difficult-to-treat population was only 10%. More data on treatment-experienced patients were not available. Therefore, the FDA performed a post-hoc analysis and estimated that the response rate for genotype 1 prior non-responders would be approximately 71% with sofosbuvir/PegIFN/RBV based on the NEUTRINO study, using treatment-naïve patients with unfavorable characteristics such as advanced fibrosis, IL28B non-CC subgenotype, and high HCV RNA viremia. 13 In HCV/HIV co-infected patients, the response rate to sofosbuvir is very similar to HCV mono-infected patients. Sofosbuvir plus PegIFN/RBV for 12 weeks resulted in SVR of 89%. 34 A 24-week course of sofosbuvir and RBV yielded an SVR of 75% (82% for genotype 1a and 54% for genotype 1b) for co-infected patients in the PHOTON study, and should not be considered due to the lower SVR. 35 In the PHOTON study, among 31 patients taking boosted atazanavir, 77% developed grade 3 hyperbilirubinemia, and 5 patients required a change in ART. Indirect hyperbilirubinemia, a common laboratory abnormality in HIV patients who are on atazanavir, results from an inhibitory competition by atazanavir of the uridinglucuronosyltransferase (UGT) 1A1 enzyme, which is responsible for bilirubin conjugation. Indirect hyperbilirubinemia is increased in patients who are also incurring hemolysis resulting from RBV. 36 Hyperbilirubinemia will resolve once treatment is completed and there is no evidence of direct liver damage resulting from coadministration of this HCV regimen with boosted atazanavir.
Boceprevir. Treatment with boceprevir requires a 4-week PegIFN/RBV induction phase followed by a 24-or 44-week course of PegIFN/RBV and boceprevir, depending on virological response. 16 The PO5411 Trial in HCV/HIV coinfected treatment-naïve patient obtained an SVR of 63% (40/64) compared with 29% (10/34) among those who received PegIFN/RBV alone. 37 This SVR rate was similar to what was seen among HCV mono-infected patients. This was the first data demonstrating that combination treatment with DAAs in the co-infected population resulted in SVR rates similar to those in the mono-infected population. Subsequent studies including C110, PHOTON, and C212 with new DAAs appear to confirm this initial finding. 32, 35, 38 Because boceprevir is a strong inhibitor of CYP3A and partially metabolized by this pathway, there are several drugdrug interactions. It is not recommended to use boceprevir with ritonavir-boosted PIs such as darunavir, atazanavir, or lopinavir [39] [40] [41] or with efavirenz or etravirine. 39, 42 Drugs that may be used with boceprevir include rilpivirine, dolutegravir, raltegravir, maraviroc, and tenofovir. 39, [43] [44] [45] [46] [47] Because of the numerous drug-drug interactions, longer course of therapy, and side effects of the combination of medications, boceprevir should no longer be used.
Telaprevir. Similar to boceprevir, the IDSA/AASLD guidelines do not recommend the use of telaprevir in HCV/ HIV co-infected patients. 7 Telaprevir is administered in combination with PegIFN/RBV for 12 weeks, followed by a RGT of an additional 12 or 36 weeks of PegIFN/RBV in treatment naïve. RGT is not recommended in cirrhotic or treatmentexperienced patients, therefore a 48-week course of therapy is needed in this population. 15 In HCV/HIV co-infected patients, the phase 2a Study C110 enrolled 38 treatment-naïve patients who received a total of 48 weeks of treatment and achieved an SVR of 74%. 38 The phase 3 INSIGHT study included 162 co-infected patients showed SVR ranging from 84% in treatment-naïve patients to 41% in prior null-responders. 48 Telaprevir is also a strong inhibitor of CYP3A4 and a substrate of P-gp. It cannot be administered with darunavir, lopinavir, or fosamprenavir, and when it is co-administered with efavirenz, the dose of telaprevir should be increased from 750 mg TID to 1125 mg TID. [49] [50] [51] Telaprevir can be safely given with etravirine, rilpivirine, dolutegravir, raltegravir, and maraviroc (with a dosage decrease to 150 mg BID). 44, 46, 47, 52 Telaprevir has a black box warning of serious skin reaction including fatal and non-fatal Stevens Johnson Syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), which occurs in less than 1% of patients. Rash (all severity) developed in 56% of patients who received telaprevir. 15 Drugs not yet FDA approved Daclatasvir. Daclatasvir is a nonstructural protein NS5A inhibitor that has pan-genotypic activity and was approved in Europe in August 2014. It is expected to be available in the US by the end of 2015. Daclatasvir has been studied in combination with PegIFN/RBV in the COMMAND-1 study, which yielded an SVR of 65% in genotype 1 patients. 53 In the European Guidelines, daclatasvir plus PegIFN/RBV for 24 weeks is recommended especially for genotype 1b. 54 The dose of daclatasvir needs to be decreased to 30 mg when administered with boosted PIs and increased to 90 mg when administered with efavirenz. 55 Daclatasvir does not need to be adjusted for any renal impairment.
Daclatasvir and sofosbuvir. When approved in the US, daclatasvir is likely to be used in combination with another DAA, such as sofosbuvir. In HCV mono-infection, daclatasvir 60 mg daily and sofosbuvir 400 mg daily with or without RBV achieved 98% SVR in treatment-naïve for 12 or 24 weeks. Treatment-experienced patients who had failed previous HCV PI therapy were treated for 24 weeks and achieved a similar response. 56 In HIV co-infected patient, ALLY-2 demonstrated greater than 96% SVR when daclatasvir and sofosbuvir were administered for 12 weeks in genotype 1-4 regardless of treatment experience. Cirrhotic patients have lower SVR, around 91%. 57 In Europe, daclatasvir and sofosbuvir is recommended for 12 weeks for noncirrhotic patients and 24 weeks for compensated cirrhotic patients. 54 Grazoprevir (MK-5172) and elbasvir (MK-874). Grazoprevir is another once daily NS3/4A PI. Following RGT, grazoprevir plus PegIFN/RBV achieved SVR rates > 90% in HCV mono-infected patients. 58 An IFN-free combination grazoprevir with elbasvir (an NS5A inhibitor) with or without RBV is now in phase 3 development. In the phase 2 C-WORTHY study, grazoprevir and elbasvir with or without RBV for 12 weeks, led to SVR of 95% in HCV mono-infected patients. In part B of the C-WORTHY trial, 59 HCV/HIV co-infected patients on an NRTI plus raltegravir were evaluated for grazoprevir/elbasvir with or without RBV for 12 weeks. SVR was 96% for patients receiving this regimen with RBV and 89% in patients receiving the regimen without RBV. 59 A recent PK study showed that grazoprevir cannot be used with boosted PIs, 60 and that there is no interaction between grazoprevir and either tenofovir or raltegravir. 20 Elbasvir does not interact with tenofovir or raltegravir but co-administration does lead to decreased levels of elbasvir when combined with efavirenz. 19 Ritonavir-boosted lopinavir, atazanavir, and darunavir increased levels of elbasvir, therefore should not be co-administered. 18 Dolutegravir can be used with these drugs, but additional data is needed on rilpivirine.
Daclatasvir and asunaprevir. The combination of daclatasvir (NS5A inhibitor) with asunaprevir (NS3/4A PI) showed an SVR of 84% in cirrhotic patients and 85% in noncirrhotic genotype 1b patients. Among cirrhotic patients, SVR was 91% in treatment naïve, 87% in prior non-responders and 81% in IFN-ineligible/intolerant groups. 61 This regimen was approved in Japan in July 2014 because of the high prevalence of 1b. Asunaprevir is not being pursued for FDA approval in the US.
Faldaprevir. Faldaprevir, a second-generation PI, has been recently withdrawn from further drug development due to the rapidly changing HCV market in which all oral therapy is an expectation. STARTVERSO 4 used faldaprevir with PegIFN/RBV with RGT and was the largest HCV/HIV coinfected treatment trial. Faldeprevir 240 mg was used with efavirenz-based ART and 120 mg with boosted-PIs, raltegravir, and marviroc. The overall SVR was 72%. 62 
Genotype 2
The IDSA/AASLD recommendations support the use of sofosbuvir and RBV for 12 weeks in genotype 2 patients who are HCV treatment-naïve or -experienced and extended to 16 weeks if the patient has cirrhosis. Sofosbuvir plus RBV for 12 weeks achieved SVR rates greater than 95% in treatmentnaïve patients in both the FISSION and VALENCE studies. 33, 63 SVR for treatment-experienced genotype 2 patients were 90% in the VALENCE study and 82% in the FUSION study. 63, 64 In cirrhotic patients, SVR for genotype 2 patients treated with sofosbuvir and RBV for 12 weeks were 100% and 88% for treatment-naïve and -experienced patients, respectively. In HCV/HIV co-infected patients, sofosbuvir and RBV for 12 weeks achieved SVR of 88% in treatmentnaïve patients in the PHOTON study. In treatment-experienced patients who received 24 weeks of sofosbuvir and RBV, SVR were 92%. 65 Thus, IFN-free treatment for genotype 2 is now considered the standard of care.
Genotype 3
In genotype 3, sofosbuvir and RBV is recommended for 24 weeks. Sofosbuvir and RBV for 24 weeks led to SVR of 93% in treatment-naïve patients and 78% in treatment-experienced patients based on data from the VALENCE study. In genotype 3 cirrhotic patients, sofosbuvir and RBV for 24 weeks had SVR of 92% for treatment-naïve and 60% for treatment-experienced. 63 Alternatively, sofosbuvir plus PegIFN/RBV for 12 weeks may be considered in IFN-eligible patients, which resulted in 83% SVR in treatmentexperienced mono-infected patients, of whom 55% were cirrhotic. 66 Another option now available with limited data is sofosbuvir/ledipasvir with RBV for 12 weeks with SVR of 100% in treatment-naïve patients and 82% in treatmentexperienced patients. 67, 68 Additionally, the European Guidelines have added daclatasvir and sofosbuvir for 12 weeks in treatment-naïve and 24 weeks in treatment -experienced patients. In the phase 2b trail, daclatasvir and sofosbuvir with or without RBV for 24 weeks in treatment-naïve, non-cirrhotic patients had SVR rate of 89%. 56 The ALLY-3 trial using the same regimen without RBV for 12 weeks yield SVR of 90% in treatment-naïve and 86% in treatment-experienced patients. 69 In HCV/HIV co-infected patients, sofosbuvir and RBV for 12 weeks achieved SVR of 67% in treatment-naïve patients in the PHOTON study. In treatment-experienced patients who received 24 weeks of sofosbuvir and RBV, SVR was 94%. 65 For genotype 3 patients, a longer course of sofosbuvir and RBV therapy is needed which also incurs a higher cost.
Genotype 4
Treatment options for genotype 4 have significantly increased based on the revised guidelines. 7 The PEARL-I study showed SVR of 100% in both treatment-naïve and -experienced patients with ombitasvir and paritaprevir/ritonavir with RBV and SVR of 91% in treatment-naïve patients with ombitasvir and paritaprevir/ritonavir only. 70 Clinical trials using sofosbuvir/ledipasvir for 12 weeks for genotype 4 showed SVR of 95% in 21 patients. 71 Sofosbuvir plus RBV for 24 weeks has been shown to be highly effective with 100% SVR in a small Egyptian study. 72 Alternatively, sofosbuvir plus PegIFN/RBV for 12 weeks had an SVR rate of 96% in the NEUTRINO study. An alternative regimen for treatmentnaïve is sofosbuvir and simeprevir with or without RBV for 12 weeks, based on in vitro and in vivo activity of simeprevir for genotype 4; clinical studies are planned. 54 Also daclatasvir and sofosbuvir for 12 weeks in treatment-naïve and 24 weeks in treatment-experienced can be considered.
Currently, there are no data on DAAs in HCV/HIV coinfected genotype 4 patients. However, the above treatment regimens for HCV mono-infected can be applied to coinfected patients with the caution regarding DAA and HAART interactions.
Genotypes 5 and 6
IDSA/AASLD guidelines recommend PegIFN, RBV, and sofosbuvir for 12 weeks for interferon-eligible patients in genotype 5. The NEUTRINO study showed 100% SVR in genotype 5 (n = 1) and 6 (n = 6) patients. 33 For genotype 6, sofosbuvir/ledipasvir for 12 weeks is recommended based on limited data showing SVR of 96%. 68 European guidelines recommend use of sofosbuvir and RBV for 24 weeks in interferon-ineligible patients.
Real-World Experience
Based on the experience with teleparevir and boceprevir, it is now known that the real world SVR data are slightly lower than clinical trials. 73 It has also shown that the uptake of triple therapy treatment in HCV/HIV patients is low (39%), even in treatment-eligible patients. 74 This points out the difficulties in treating HCV/HIV patients in the real world. Since the approval of sofosbuvir and simeprevir in late 2013, data on using these DAA in the real world have been presented, including in HIV patients. Data from the TRIO network show that simeprevir/sofosbuvir with or without RBV for 12 weeks in genotype 1 HCV mono-infected patients had SVR of 82% and sofosbuvir plus RBV for 12 weeks for genotype 2 patients had SVR of 84%. 75 Similar data from HCV-TARGET showed SVR at post-treatment week 4 of 89% in simeprevir/ sofosbuvir with or without RBV for 12 weeks in genotype 1 patients. 76 In both real-world data, there are no significant differences between regimens with or without RBV. One single center treated 22 HIV/HCV co-infected patients with sofosbuvir/simeprevir with or without RBV reported SVR post-treatment week 4 of 96%. 77 In the real world, it appears that SVR is approximately 10% lower than SVR reported from clinical trials, but long-term data are needed. The advancement of HCV treatment is reminiscent of the evolution of HIV therapy, albeit at a much faster pace. Moving forward, an NS5A or NS5B polymerase inhibitor will need to be the backbone of the regimen (similar to NRTI in HIV regimens). In HCV/HIV co-infected patients, ART should be initiated or adjusted based on preferred HCV treatment and the potential for drug-drug interactions. Numerous treatment options will likely soon be available for the HCV/HIV co-infected patient, but important drug-drug interactions studies are still needed so that patients may be safely treated without risking HIV virologic failure or HCV drug toxicity. In time, these drugs will help to increase life expectancy in those patients living with both HIV and HCV.
